Targeting a Weak Link in Pediatric Brain Cancer
A new study has found that a particularly deadly form of pediatric brain tumor may have a weakness that could inspire future treatments.
Browsing: "Cancer"
New Epigenetic Regulation of Cancer Uncovered
Scientists have identified a new gene that can inhibit a multi-protein complex, possibly increasing the risk of cancer, according to a new study published in Science Advances.
Medical Student Pursues Glioblastoma Treatments in the Lab
Medical student Shivani Baisiwala investigates glioblastoma in the laboratory of Atique Ahmed, PhD, while also pursuing pro-bono healthcare consulting and finding time to explore Chicago’s neighborhoods.
Faculty Explore Policy Solutions for Cancer Drug Delivery
Sheetal Kircher, MD, ’11 GME, is laser-focused on cancer drug distribution and pricing: she spent a year as a health policy fellow at the ASCO and published a paper on the topic in JAMA.
Pancreatic Cancer Drug, High-Fat Diet Linked to Liver Disease Risk
An emerging class of cancer drugs has shown promise in treating pancreatic cancer, but the drugs may cause severe liver damage when combined with high-fat diets, according to study published in PNAS.
Cell Polarity Linked to Cell Adhesion
Scientists discovered a new link between cell polarity and cell adhesion, according to a study published in the Journal of Cell Biology.
Feinberg/Nature Conference Explores Epigenetics
Feinberg partnered with Nature Genetics and Nature Medicine to host the Chicago Science 2019: Epigenetics and Genome Editing conference.
Radiation Plus Chemotherapy Doesn’t Improve Endometrial Cancer Recurrence-Free Survival
In a surprising new finding, radiation combined with chemotherapy did not increase recurrence-free survival in women with stage III/IVA endometrial cancer following surgery.
Uncovering Enzyme’s Dual Role in Cancer Suppression and Growth
A new Northwestern Medicine study has uncovered how a key enzyme in mitochondria can function as both a cancer suppressor and cancer promoter.
Drug Improves Survival in Relapsed Chronic Lymphocytic Leukemia
A combination of idelalisib and rituximab is an effective and safe treatment for patients with relapsed chronic lymphocytic leukemia, according to the results of a phase III clinical trial.